Clinical update on the use of recombinant factor VII
- 1 January 1995
- book chapter
- Published by Springer Nature
- Vol. 386, 163-174
- https://doi.org/10.1007/978-1-4613-0331-2_15
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Experience With Recombinant Factor VIIA in an Infant Hemophiliac With Inhibitors to FVIILC Undergoing Emergency Central Line PlacementJournal of Pediatric Hematology/Oncology, 1993
- A therapeutic alternative for haemophiliacs with inhibitorsActa Paediatrica, 1992
- PROLONGED RECOMBINANT ACTIVATED FACTOR VII (rFVIIa) TREATMENT FOR SEVERE BLEEDING IN A FACTOR‐IX‐DEFICIENT PATIENT WITH AN INHIBITORBritish Journal of Haematology, 1991
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- Factor VIIa in the treatment of haemophiliaBlood Coagulation & Fibrinolysis, 1990
- The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experienceArchives of Internal Medicine, 1989
- Hematologic management of hemophilia A for surgeryJAMA, 1985
- Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors.JCI Insight, 1983
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980